Risk factors for osteoporosis in inflammatory bowel disease patients

Table 1 Infliximab effects on bone mineral density in Crohn’s disease

Ref.	Study design1	Participants number	Endpoints	Results
Miheller et al[69]	Prospective	29 CD patients	Determine the effects of IFX on bone metabolism in CD patients	IFX improves bone metabolism in CD independently from the behavior of the disease
Abreu et al[70]	Prospective	38 CD patients	Assess the ability of IFX to increase bone formation measured by markers of bone turnover in active CD patients	Treatment with IFX was associated with increased markers of bone formation
Franchimont et al[71]	Prospective	71 CD patients, 68 controls	Assess the evolution of markers of bone turnover after IFX treatment for active CD	IFX induces improvement in biochemical markers of bone turnover
Mauro et al[72]	Retrospective	15 CD patients, 30 controls	Assess whether treatment with IFX had a beneficial effect on lumbar bone mass	Treatment with IFX was associated with significant increases in lumbar bone area, BMC and BMD in CD patients
Pazianas et al[73]	Retrospective	61 CD patients	Evaluate the effects of IFX administration on BMD in CD patients	IFX may work in synergy with bisphosphonates to provide additional increases in BMD in CD patients

¹All were cohort study. CD: Crohn disease; IFX: Infliximab; BMC: Bone mineral content; BMD: Bone mineral density.